Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GH vs BLLN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BLLN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

BLLN Overall Winner 6-Pillar Tally: GH 0 – 6 BLLN Matrix Metrics: GH 3 – 7 BLLN

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Guardant Health, Inc. (GH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GH carries a Unified Composite Score of 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin), whereas BLLN carries 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While GH currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -39.4% operating margin) and revenue trajectory (+47.2% vs. +36.1% YoY).
  • Technical & Structure Timing Caution: GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2); meanwhile BLLN is in a Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GH vs BLLN
GH NASDAQ
Guardant Health, Inc. Common Stock
Services-Medical Laboratories
$144.03
-5.06% 1D
Market Cap $20.5B
TTM Revenue $1.28B
Forward P/E N/M
Beta / 30D Vol 1.32β · 56% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 19.0 Fund 48.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.2 · SMA20: $164.87 · SMA50: $168.30
BLLN US Equity Head-to-Head Winner
BillionToOne, Inc.
Services-Medical Laboratories
$96.31
-8.41% 1D
Market Cap $5.0B
TTM Revenue $437M
Forward P/E 61.3x
Beta / 30D Vol 1.44β · 42% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 27.0 Fund 53.0 Flow 71.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.4 · SMA20: $109.99 · SMA50: $106.93

6-Pillar Scorecard Institutional Category Breakdown (GH 0 – 6 BLLN)

Columns: Metric · GH · BLLN
1. Valuation Multiples BLLN
Forward P/E N/M 61.3x
Trailing P/E N/M 114.3x
PEG Ratio N/M N/M
EV / Revenue 16.6x 10.5x
2. Growth & Scale BLLN
Revenue Growth (YoY) +36.1% +47.2%
Earnings Growth (YoY) +0.0% +220.0%
TTM Revenue (USD) $1.28B $437M
Market Cap $20.5B $5.0B
3. Profitability & Quality BLLN
Gross Margin 65.2% 71.4%
Operating Margin -39.4% 10.2%
Net Profit Margin -37.9% 10.5%
Return on Equity (ROE) 0.0% 13.2%
4. Balance Sheet & Cash Flow BLLN
Cash Generation (TTM) -$232M $34M
Cash Flow Margin -18.2% 7.8%
Net Cash / Leverage $665M Net Debt $421M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BLLN
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 72.2% (31st %ile) 113.8% (26th %ile)
Put/Call OI Skew 3.50x (Put-Skewed) 1.21x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat BLLN
OpEx & R&D Intensity N/A 61.2% of Rev ($267M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GH (3) vs BLLN (7)
Institutional Metric GH BLLN Criterion Row Edge
Market Capitalization
Scale
$20.5B $5.0B Larger Scale GH
Trailing P/E Ratio
Valuation
N/M 114.3x Lower Multiple BLLN
Forward P/E Ratio
Valuation
N/M 61.3x Lower Multiple BLLN
Revenue Growth (YoY)
Growth
+36.1% +47.2% Higher Growth BLLN
Operating Margin (TTM)
Profitability
-39.4% 10.2% Higher Margin BLLN
Net Profit Margin
Profitability
-37.9% 10.5% Higher Margin BLLN
Return on Equity (ROE)
Capital Efficiency
0.0% 13.2% Higher ROE BLLN
52-Week Range Position
Momentum
60% ($75–$191) 39% ($62–$150) Stronger Trend GH
Beta / 30D Volatility
Risk Regime
1.32β · 56% Vol 1.44β · 42% Vol Lower Realized Risk BLLN
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 45.8 / 100 (HOLD) Higher Composite GH
Trailing 12M Revenue (USD)
Operating Scale
$1.28B $437M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.2% 71.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.6x EV/Rev N/M PEG · 10.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$232M ($665M Net Debt) $34M ($421M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLLN +7.35 pp
GH: -9.19% · BLLN: -1.84%
3M Horizon BLLN +19.51 pp
GH: -10.05% · BLLN: +9.46%
6M Horizon GH +38.73 pp
GH: +50.56% · BLLN: +11.83%
1Y Horizon GH +45.46 pp
GH: +53.01% · BLLN: +7.55%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GH Revenue BLLN Revenue GH Op. Margin BLLN Op. Margin Margin Leader
FY2018 $90M N/A -102.5% N/A GH
FY2019 $210M N/A -38.4% N/A GH
FY2020 $290M N/A -88.9% N/A GH
FY2021 $370M N/A -110.0% N/A GH
FY2022 $450M N/A -121.1% N/A GH
FY2023 $560M $70M -100.1% -96.9% BLLN
FY2024 $740M $150M -60.0% -30.9% BLLN
FY2025 $980M $310M -44.5% 5.3% BLLN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GH CONSOLIDATION
96d in phase · OBV DISTRIBUTION
Current IV 72.2%
IV Percentile 31st %ile
Put/Call OI Skew 3.50x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact GH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BLLN BREAKDOWN
78d in phase · OBV DISTRIBUTION
Current IV 113.8%
IV Percentile 26th %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GH Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $20.5B market capitalization and -39.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BLLN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 61.2% of Rev ($267M)
90D Engineering Disclosures 0 Published

Investor FAQ GH vs BLLN Key Questions & Quantitative Answers

As of Nov 16, 2026, BillionToOne, Inc. (BLLN) is the stronger overall head-to-head candidate over Guardant Health, Inc. (GH) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GH carries a Unified Composite Score of 48.4/100 (HOLD) at $144.03 (N/M Forward P/E, -39.4% operating margin), whereas BLLN carries 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While GH currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. BLLN 45.8/100 HOLD), BLLN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -39.4% operating margin) and revenue trajectory (+47.2% vs. +36.1% YoY). Technical & Structure Timing Caution: GH trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 34.2); meanwhile BLLN is in a Breakdown options structure phase (RSI 34.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLLN leads the Growth & Scale pillar: GH posts +36.1% YoY revenue growth and +0.0% YoY earnings growth on $1.28B TTM revenue (65.2% gross margin, -39.4% operating margin), compared with BLLN at +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GH cumulative revenue shifted +988.9% while BLLN shifted +342.9%. In operating R&D and SG&A reinvestment, GH deploys N/A (0 90-day corporate R&D disclosures) versus 61.2% of Rev ($267M) (0 disclosures) for BLLN.

BLLN screens cheaper on headline valuation multiples. GH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.6x EV/Revenue (-18.2% FCF margin), whereas BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GH (0.0% ROE) versus BLLN (13.2% ROE) capital efficiency.

In options market volatility and institutional positioning, GH carries 72.2% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 3.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.32β · 56% Vol realized risk). By comparison, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.